SCHEMBL6507914

SCHEMBL6507914

CCOc1ccccc1C(=O)Nc1ccc2[nH]nc(-c3ccc(F)cc3)c2c1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TTK P33981 2/20 0.54
MAPK8 P45983 2/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
RXFP1 Q9HBX9 3/20 0.52
KCNK3 O14649 2/20 0.52
KCNK9 Q9NPC2 2/20 0.52
MAPT P10636 3/20 0.52
JAK2 O60674 1/20 0.51
JAK1 P23458 1/20 0.51
LRRK2 Q5S007 3/20 0.50
NTRK1 P04629 1/20 0.50
ALDH1A1 P00352 1/20 0.49
HPGD P15428 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
LMNA P02545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5380305 0.89 NTRK1 (0.58) MEN1KMT2ARXFP1KCNK3KCNK9
SCHEMBL6322350 0.85 LRRK2 (0.56) MEN1KMT2AJAK2JAK1LRRK2
SCHEMBL6322335 0.83 KDM4E (0.55) MEN1KMT2AMAPTJAK2JAK1
SCHEMBL5382135 0.81 LRRK2 (0.58) LRRK2
SCHEMBL5372770 0.80 JAK2 (0.66) KCNK3KCNK9JAK2JAK1LRRK2
SCHEMBL4428095 0.79 MEN1 (0.77) MEN1KMT2ARXFP1KCNK3KCNK9
SCHEMBL5377833 0.79 LRRK2 (0.47) JAK2JAK1LRRK2NTRK1
SCHEMBL5381989 0.78 AURKA (0.60) KCNK3KCNK9JAK2JAK1LRRK2
SCHEMBL5372220 0.76 MAP2K4 (0.65) KMT2AMAPTJAK2JAK1LRRK2
SCHEMBL8251896 0.76 CSNK1D (0.56) MEN1KMT2AJAK2JAK1LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith SIGNAL PHARMACEUTICALS, LLC 2005-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009876-A1 Indazole compounds, compositions thereof and methods of treatment therewith GPR119, JAK3, IGF1R TTK 714/4885MAPK8 91/4885MEN1 4592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.